Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-04-19
2011-04-19
Peng, Bo (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S227100, C435S005000, C435S235100, C435S193000, C435S194000
Reexamination Certificate
active
07927601
ABSTRACT:
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other antagonists of HBV DNA polymerase activity and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants. These assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular the resistant HBV variants of the present invention. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
REFERENCES:
patent: 2006/0051743 (2006-03-01), Bartholomeusz et al.
patent: 2309379 (2001-12-01), None
patent: WO 03/066841 (2003-08-01), None
patent: WO 03/087351 (2003-10-01), None
patent: WO 2004/031224 (2004-04-01), None
patent: WO 2005/042733 (2005-05-01), None
Bartholomeusz, S.L. et al. 2005 “Mechanistic basis for hepatitis B virus resistance to acyclic nucleoside phosphonate analogues, adefovir and tenofovir”Hepatology42(4): Suppl 1, p. 594A (Abstract).
Gallant, J.E. and Deresinski, S. 2003 “Tenofovir disproxil fumarate”Clin Infect Dis37(7):944-950.
GenBank Accession No. AY217375, Hepatitis B virus isolate 599, complete genome, Jul. 15, 2004. Cites Luo, K. et al. 2004 “The putative recombination of hepatitis B virus genotype B with pre-C/C region of genotype C”Virus Genes29(1): 31-41. (Abstract only).
Sheldon, J. et al. 2005 “Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir”Antiviral Therapy10:727-734.
Torresi, J. 2002 “The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus”J Clin Virol25:97-106.
Walters, K-A. et al. 2003 “Generation of stable cell lines expressing lamivudine-resistant hepatitis B virus for antiviral-compound screening”Antimicrobial Agents and Chemotherapy47(6):1936-1942.
Delaney IV, W.E. et al. 2006. “Intracellular metabolism andin vitroactivity of Tenofovir against Hepatitis B virus”Antimicrobial Agents and Chemotherapy50(7): 2471-2477.
Kuo, A. et al. 2004. “Tenofovir Disoproxil Fumarate for the treatment of Lamivudine-resistant Hepatitis B”Clinical Gastroenterology and Hepatology2: 266-272.
Stuyver, L.J. et al. 2001. “Nomenclature for antiviral-resistant human Hepatitis B virus mutations in the polymerase region”Hepatology33(3): 751-757.
Supplementary European Search Report, European Patent Application No. EP 05 79 1326, dated Jan. 18, 2008.
Bartholomeusz Angeline Ingrid
Rodes Berta
Sheldon Julie
Soriano Vincent
Fundacion Investigacion y Educacion En Sida
Knobbe Martens Olson & Bear LLP
Melbourne Health
Peng Bo
LandOfFree
Variants of hepatitis B virus with resistance to anti-viral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variants of hepatitis B virus with resistance to anti-viral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of hepatitis B virus with resistance to anti-viral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725871